IFRX – inflarx n.v. (US:NASDAQ)

DELAYED
$ usd
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
1D
5D
1M
3M
YTD
1Y
3Y
1 Day IFRX SPY QQQ SPX
Date
Time
Symbol
Company Name
Action
%Chg
8/7/2025
07:30 am
ifrx
inflarx n.v.
BEAT
-1.6%
5/7/2025
07:30 am
ifrx
inflarx n.v.
BEAT
-8.0%
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions?
The answers are right here.
Date
Time
Symbol
Headline
Impact
Stock Stats
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
Top News Gainers
3/31 InflaRx Doses First Patient in Multicenter Randomized Clinical Trial in Severe Progressed COVID-19 Pneumonia in Europe upon Receipt of Initial Positive Human Data with InflaRx’s anti-C5a Technology 50.0%
4/29 Form 20-F InflaRx N.V. For: Dec 31 30.0%
2/14 Form SC 13G/A InflaRx N.V. Filed by: Cormorant Asset Management, LP 23.6%
2/19 InflaRx to Present at Upcoming SVB Leerink Global Healthcare Conference 14.9%
2/26 Form 6-K InflaRx N.V. For: Feb 26 14.1%
6/12 Inflarx NV (NASDAQ: IFRX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.75 price target on the stock. 6.1%
1/8 Inflarx NV (NASDAQ: IFRX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $4.00 price target on the stock. 5.2%
10/23 Inflarx NV (NASDAQ: IFRX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 4.9%
6/14 Form 6-K InflaRx N.V. For: Jun 14 4.7%
6/13 InflaRx Treats First Patient in Phase IIa Clinical Trial with Lead Candidate IFX-1 in Pyoderma Gangraenosum 3.6%
Top News Decliners
6/5 Form 6-K InflaRx N.V. For: Jun 05 -91.8%
4/1 Form 6-K InflaRx N.V. For: Mar 31 -34.4%
3/2 Form 6-K InflaRx N.V. For: Mar 02 -23.5%
11/7 Form 6-K InflaRx N.V. For: Nov 07 -21.7%
7/18 Form 6-K InflaRx N.V. For: Jul 18 -16.0%
5/23 Form 6-K InflaRx N.V. For: May 23 -10.2%
4/29 InflaRx Reports Full Year 2019 Financial & Operating Results -7.8%
11/14 Form 6-K InflaRx N.V. For: Nov 14 -5.3%
4/9 Form 6-K InflaRx N.V. For: Apr 09 -3.1%
2/26 InflaRx Announces Positive Initial Data from Ongoing Phase IIa Open Label Study with IFX-1 in Patients Suffering from Pyoderma Gangraenosum -3.0%

Don’t Miss Out On The Next BIG Stock Move

Thanks for submitting the form.
IFRX – inflarx n.v. (US:NASDAQ)
DELAYED
$ usd
1D
5D
1M
3M
YTD
1Y
3Y
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
IFRX
SPY
QQQ
SPX
IFRX – inflarx n.v. (US:NASDAQ)
DELAYED
$ usd
1D
5D
1M
3M
YTD
1Y
3Y
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
IFRX SPY QQQ SPX
Stock Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
Stock Stats
Order Stats
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
News
12/11
07:30 am
ifrx
Low
InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904
12/4
07:18 am
ifrx
Medium
InflaRx (NASDAQ:IFRX) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
12/3
08:06 am
ifrx
Low
InflaRx (NASDAQ:IFRX) was downgraded by analysts at Leerink Partners to a "market perform" rating.
12/3
08:05 am
ifrx
Medium
InflaRx (NASDAQ:IFRX) was given a new $2.00 price target on by analysts at Leerink Partners.
11/11
07:03 am
ifrx
Medium
InflaRx (NASDAQ:IFRX) had its "outperform" rating reaffirmed by analysts at Raymond James Financial, Inc..
10/21
07:20 am
ifrx
Medium
InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference
10/14
12:15 pm
ifrx
Low
InflaRx (NASDAQ:IFRX) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
8/7/2025
07:30 am
ifrx
-1.6%
BEAT
5/7/2025
07:30 am
ifrx
-8.0%
BEAT
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions? The answers are right here.
12/3
08:36 am
Downgrades
Outperform
Market Perform
Leerink Partners
Low
-2.9%
12/3
08:06 am
Downgrades
Market Perform
Leerink Partners
Low
-2.9%
12/3
06:32 am
Downgrades
OUTPERFORM
MARKET PERFORM
LEERINK
Low
-1.9%
12/3
06:10 am
Downgrades
OUTPERFORM
MARKET PERFORM
LEERINK
Low
-1.0%
11/11
07:03 am
Reiterates
Outperform
Outperform
Raymond James Financial, Inc.
Medium
7.1%
Show more
Top News Gainers
3/31 InflaRx Doses First Patient in Multicenter Randomized Clinical Trial in Severe Progressed COVID-19 Pneumonia in Europe upon Receipt of Initial Positive Human Data with InflaRx’s anti-C5a Technology 50.0%
4/29 Form 20-F InflaRx N.V. For: Dec 31 30.0%
2/14 Form SC 13G/A InflaRx N.V. Filed by: Cormorant Asset Management, LP 23.6%
2/19 InflaRx to Present at Upcoming SVB Leerink Global Healthcare Conference 14.9%
2/26 Form 6-K InflaRx N.V. For: Feb 26 14.1%
6/12 Inflarx NV (NASDAQ: IFRX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.75 price target on the stock. 6.1%
1/8 Inflarx NV (NASDAQ: IFRX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $4.00 price target on the stock. 5.2%
10/23 Inflarx NV (NASDAQ: IFRX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 4.9%
6/14 Form 6-K InflaRx N.V. For: Jun 14 4.7%
6/13 InflaRx Treats First Patient in Phase IIa Clinical Trial with Lead Candidate IFX-1 in Pyoderma Gangraenosum 3.6%
Top News Decliners
6/5 Form 6-K InflaRx N.V. For: Jun 05 -91.8%
4/1 Form 6-K InflaRx N.V. For: Mar 31 -34.4%
3/2 Form 6-K InflaRx N.V. For: Mar 02 -23.5%
11/7 Form 6-K InflaRx N.V. For: Nov 07 -21.7%
7/18 Form 6-K InflaRx N.V. For: Jul 18 -16.0%
5/23 Form 6-K InflaRx N.V. For: May 23 -10.2%
4/29 InflaRx Reports Full Year 2019 Financial & Operating Results -7.8%
11/14 Form 6-K InflaRx N.V. For: Nov 14 -5.3%
4/9 Form 6-K InflaRx N.V. For: Apr 09 -3.1%
2/26 InflaRx Announces Positive Initial Data from Ongoing Phase IIa Open Label Study with IFX-1 in Patients Suffering from Pyoderma Gangraenosum -3.0%